Form 4: Pasithea Therapeutics Director Alfred J. Novak Acquires Stock Options

Director Alfred J. Novak acquired 5,000 stock options in Pasithea Therapeutics Corp. on March 1, 2024, according to a Form 4 filing.

Summary

• Alfred J. Novak, a director of Pasithea Therapeutics Corp., acquired 5,000 stock options on March 1, 2024.
• The options have an exercise price of $8.34.
• The options vest in three annual installments of 33% beginning on the one-year anniversary of the grant date, provided Novak remains a director.
• The options expire on February 28, 2034.
• The grant was made under the Issuer's 2023 Stock Incentive Plan.
• A 1-for-20 reverse stock split was effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The reverse stock split is a neutral to slightly negative event, but the option grant itself doesn't necessarily indicate strong positive or negative sentiment.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring such filings can provide insights into management's sentiment and potential future actions.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, director, Pasithea Therapeutics, KTTA, Form 4, insider trading, Alfred J. Novak, reverse stock split, equity awards, vesting